Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 5/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.53 |
| ▸ | HTR3B | O95264 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319640 | 1.00 | CHRNA7 (0.58) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL3320988 | 1.00 | CHRNA7 (0.58) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL8050322 | 0.82 | CA12 (0.55) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL14514757 | 0.82 | CA12 (0.55) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL13525452 | 0.82 | CA12 (0.55) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL16790664 | 0.82 | CA12 (0.55) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL5892019 | 0.82 | CA12 (0.55) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL6683718 | 0.82 | CA12 (0.55) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL9303682 | 0.82 | CA12 (0.55) | CHRNA7CA12CA1CA2CA9 | |
| SCHEMBL879026 | 0.82 | CA12 (0.55) | CHRNA7CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2020-04-09 | — | — | US | disclosed |
| US-20180037957-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2018-02-08 | — | — | US | disclosed |
| EP-2931315-B1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2017-11-29 | — | — | EP | disclosed |
| US-9828642-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2017-11-28 | — | — | US | disclosed |
| EP-2931315-A2 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | Novartis AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-20150275303-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2015-10-01 | — | — | US | disclosed |
| EP-2768507-A2 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | Novartis AG (CH) | 2014-08-27 | — | — | EP | disclosed |
| US-20140228398-A1 | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| WO-2013057687-A2 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012146515-A1 | ALKALOID ESTER AND CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-11-01 | — | — | WO | disclosed |
| US-20120276018-A1 | ALKALOID ESTER AND CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-11-01 | — | — | US | disclosed |
| WO-2012127393-A1 | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2012-09-27 | — | — | WO | disclosed |
| EP-2480228-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | Novartis AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-20120172346-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG | 2012-07-05 | — | — | US | disclosed |
| US-20120157464-A1 | USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA | NOVARTIS AG | 2012-06-21 | — | — | US | disclosed |
| US-20100125063-A1 | COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS | NOVARTIS AG | 2010-05-20 | — | — | US | disclosed |
| EP-2135609-A1 | Combinations of nicotinic acetylcholine alpha 7 receptor agonists | Novartis AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20080306081-A1 | Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists | NOVARTIS AG (CH) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150275303-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885CA12 2347/4885CA1 1331/4885 |
| US-20120276018-A1 | ALKALOID ESTER AND CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHRM3, BCHE, CHRM1 | CHRNA7 42/4885CA12 316/4885CA1 320/4885 |
| US-20180037957-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885CA12 2347/4885CA1 1331/4885 |
| US-20140228398-A1 | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE | CHRNA5, GRM5, CHRNA7 | CHRNA7 3/4885CA12 4202/4885CA1 2562/4885 |
| US-20120172346-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885CA12 4389/4885CA1 3269/4885 |
| US-20100125063-A1 | COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS | CHRNA7, CHRNA4, CHRNA10 | CHRNA7 1/4885CA12 4409/4885CA1 2276/4885 |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885CA12 4389/4885CA1 3269/4885 |
| US-20080306081-A1 | Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists | CHRNA7, CHRNA4, CHRNA10 | CHRNA7 1/4885CA12 4333/4885CA1 1999/4885 |
| US-20120157464-A1 | USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA | ATXN2, CDR2, ATXN2L | CHRNA7 205/4885CA12 3729/4885CA1 1765/4885 |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885CA12 2347/4885CA1 1331/4885 |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885CA12 4389/4885CA1 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.